

Aequus Pharmaceuticals Inc.

10:20 10 Jan 2020

Aequus to broaden patient reimbursement in Canada for glaucoma-treatment product Vistitan

Aequus Pharmaceuticals Inc (CVE:AQS) (OCTMKTS:AQSZF) announced Friday that it has advanced the filings for provincial reimbursement in Quebec and British Columbia for its flagship glaucoma-treatment product Vistitan.

If successful, the company noted that the additional coverage would advance sales in the second and third largest markets in Canada and would trigger an increase in the percentage of total revenue that Aequus receives from its partner.

Meanwhile, investors cheered the news, sending Aequus shares up 10% to US\$0.07 in morning trading on the OTC markets in New York.

READ: Aequus and Medicom Healthcare ink pact to advance ophthalmology products in US

Aequus has been consistently growing market share of Vistitan in Ontario and Alberta and is continuing its expansion of access for Canadian patients in both British Columbia and Quebec.

"The bimatoprost market in Canada exceeds \$55 million, nearly 36% of that is in these two provinces," CEO Doug Janzen said in a statement.

"Whilst our sales team has done a great job in Ontario and Alberta growing our volume share by over 30% in the last 12 months, we want to replicate that in both Quebec and BC following an anticipated positive reimbursement outcome."

Ian Ball, chief commercial officer at Aequus, said the additional coverage benefits the company in two ways.

"There is a compelling case for Vistitan reimbursement in Canada and we look forward to a decision shortly from BC and later in the year from INNESS in Quebec," he said.

"In addition to expanding the markets for Vistitan, the company will also earn an increase in the revenue share from our partner Sandoz and expects to further bolster our ophthalmology offering with the launch of the Evolve products in the coming months."

The company said it will provide a further update on the anticipated launch timelines for Evolve by the end of January, as a final notification from the auditor is expected by its partner.

Aequus, based in Vancouver, is a specialty pharma company focused on commercializing drugs meant for the highly specialized areas of neurology, organ transplant and ophthalmology.


Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Price: 0.11

Market Cap: \$8.85 m

1 Year Share Price Graph



April 2019 September 2019 March 2020

Share Information

Code: AQS

Listing: TSX-V

52 week High Low
0.215 0.065

Sector: Pharma & Biotech

Website: www.aequuspharma.ca

Company Synopsis:

Aequus Pharmaceuticals Inc. is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).